¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ë±¸°¡Å縯´ëÇб³º´¿ø ¸Á¸· : 2020-02-29

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ë±¸°¡Å縯´ëÇб³º´¿ø ¸Á¸· : 2020-02-29
±³À°ÀÏÀÚ : 2020-02-29
±³À°Àå¼Ò : ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ  
±³À°ÁÖÁ¦ : ¸Á¸·
ÁÖÃÖ±â°ü : ´ë±¸°¡Å縯´ëÇб³º´¿ø
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¾È°ú  
´ã´çÀÚ : À̽ÃÀº
¿¬¶ôó : 053-650-4728  
À̸ÞÀÏ : dcmc_ot@naver.com      
±³À°Á¾·ù : ¾È°ú      
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ´ë±¸±¤¿ª½Ã
±³À°½Ã°£ : 6 ½Ã°£ 10ºÐ  
¼¼ºÎ¼ö°­·á : 60,000¿ø      
ºñ°í »çÀüµî·Ï- Àü¹®ÀÇ 50,000¿ø, Àü°øÀÇ 40,000¿ø ÇöÀåµî·Ï- Àü¹®ÀÇ 60,000¿ø, Àü°øÀÇ 50,000¿ø °èÁ¹øÈ£ 508-13-827509-5(´ë±¸ÀºÇà, ¹é¹ÎÁÖ)      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 09:20~09:30 Multimodal imaging of type 1,2,3 CNV  Á¤Àοµ(°æ»óÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 09:30~09:40 Clinical application of OCTA in ARMD and its allied disease  ÀÌÁÖ¿ë(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 09:40~09:50 Clinical application of OCTA in DMR and BRVO  ¹Úµ¿È£(°æºÏÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 09:50~10:00 Clinical value of wide FP and FA and ICG  »ç°ø¹Î(¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 10:00~10:10 Enface OCT imaging  ¾È¼ºÁØ(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 10:10~10:20 AF imaging in retinal field  À¯½Â¿µ(°æÈñÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 10:20~10:30 Imaging of choroid  ¹Ú¼ºÇ¥(ÇѸ²ÀÇ´ë) 
Åä·Ð 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 10:30~10:45 DIscussion  () 
È޽Ġ02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 10:45~11:05 Break  () 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 11:05~11:15 Classification of various drusen  ±èÀ¯Ã¶(°è¸íÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 11:15~11:25 Dry ARMD treatment, present and emerging  ±èÇö¿õ(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 11:25~11:35 Risk factor of geographic atrophy secondary to ARMD  ÃÖ°æ½Ä(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 11:35~11:45 Update of pachychoroid diseases  ÀÌ¿ø±â(´©³×¾È°úº´¿ø) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 11:45~11:55 Treatment of wet ARMD and PCV, experience and future  °íÇüÁØ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 11:55~12:05 Myopic CNV, treatment and DDX  ½ÅÀçÇÊ(°æºÏÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 12:05~12:15 Mactel type 2 current concept  ¿ÀÀç·É(°í·ÁÀÇ´ë) 
Åä·Ð 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 12:15~12:30 DIscussion  () 
½Ä»ç 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 12:30~13:30 Lunch time  () 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 13:30~14:00 ±è½Ãµ¿ ±³¼ö ¼Ò°³ ¹× Ưº° °­¿¬  ±è½Ãµ¿(´ë±¸°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 14:00~14:10 Lessons from DRCR.net protocol I, S, T  ¼ÛÁöÈÆ(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 14:10~14:20 Brief summary of ongoing DRCR.net protocol U, V, W  À̽¿ì(µ¿±¹ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 14:20~14:30 Anti VEGF in DME  Á¶¿µÁØ(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 14:30~14:40 Steroid role in DME  ÀÌÁ¾Çö(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 14:40~14:50 Managenet of refractory DME and DMR progression in real practice  ÁøÈñ½Â(ÀÎÇÏÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 14:50~15:00 Endophthalmitis after intravitreal injection  ¹Ú¿µÈÆ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 15:00~15:10 Current management of vein occlusion  ³²µ¿Èç(°¡ÃµÀÇ´ë) 
Åä·Ð 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 15:10~15:25 Discussion  () 
È޽Ġ02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 15:25~15:40 Break  () 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 15:40~15:50 Vitrectomy for RRD(case slection, tamponade, etc)  ±èö±¸(±è¾È°úº´¿ø) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 15:50~16:00 Vitrectomy for ERM(good vision caes, inner lamellar hole)  ±èÀ±¿µ(´ë±¸°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 16:00~16:10 Vitrectomy for IOL dislocation(various method)  ±è¼º¼ö(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 16:10~16:20 Vitrectomy for macular hole(conventional/flap, prone, tmponade, etc)  ÀÌÁöÀº(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 16:20~16:30 Vitrectomy for uveitis(what cases, combine treatment, etc)  À¯Çü°ï(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 16:30~16:40 Vitrectomy for DMR(how to improve result, adjuvant, etc)  ±èÁß°ï(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 16:40~16:50 3D surgery(merits and limitation)  ¹Ú±ÔÇü(¼­¿ïÀÇ´ë) 
Åä·Ð 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 16:50~17:05 Discussion  () 
±âŸ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 17:05~17:10 Closing  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ë±¸°¡Å縯´ëÇб³º´¿ø ¸Á¸· : 2020-02-29""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Á¦12ȸ °Ç°­º¸Çè ºòµ¥ÀÌÅÍ ÀÚ·áºÐ¼®À» ÅëÇÑ ³í¹®Ãâ°£ ¿öÅ©¼¥ : 2020-02-29
´ÙÀ½±Û Á¦ 6ȸ Á¶Ç÷¸ð¼¼Æ÷ÀÌ½Ä ¾ÆÄ«µ¥¹Ì: 2020-02-29
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
93 ºÎ»ê ´ëÇѽŰæÁßÀçÄ¡·áÀÇÇÐȸ Summer Intensive Course 2018 of KSIN : 2018-08-24 0 387 2018-07-28
92 ¼­¿ï 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-08-24 0 305 2018-07-28
91 ¼­¿ï 2018³â ´ëÇÑ°©»ó¼±ÇÐȸ Ãß°èÇмú´ëȸ(8/24) : 2018-08-24 0 322 2018-07-28
90 ÀÎõ °­È­±ºÀÇ»çȸ 3Â÷ ¼¼¹Ì³ª(°üÀýº¸Á¸ Ä¡·á) : 2018-08-24 0 315 2018-07-28
89 °æ±â Á¦5Â÷ ¾Æ½Ã¾ÆºÎÀÎÁ¾¾çÇÐȸ ¿öÅ©¼ó(ASGO 5th International Workshop on Gynecologic Oncology in conjunction with 12th KSGO Workshop for Young Gynecologic Oncologists) : 2018-08-24 0 482 2018-07-28
88 ¼­¿ï ´ëÇÑÀÇ»çÇùȸ [Á¦27±â ÀÇ·áÁ¤Ã¥ÃÖ°íÀ§°úÁ¤] °Ç°­º¸Çè°ú ¹Î°£ÀǷẸÇè : 2018-08-23 0 295 2018-07-28
87 ¼­¿ï ±¹¸³ÀÇ·á¿ø 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-08-23 0 367 2018-07-28
86 ¼­¿ï ±¹¸³ÀÇ·á¿ø 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-08-22 0 474 2018-07-28
85 ¼­¿ï ´ëÇÑÀÓ»óÅëÁõÇÐȸ 2018³â Á¦2ȸ Á¤±âÇмúÁý´ãȸ : 2018-08-22 0 438 2018-07-28
84 °æºÏ ´ëÇÑôÃ߽Űæ¿Ü°úÇÐȸ ´ë±¸°æºÏÁöȸ Á¦4Â÷ Áõ·ÊÅä·Ðȸ : 2018-08-21 0 420 2018-07-28
83 Ãæ³² ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ ´ëÀüÃæûÁöȸ 8¿ù ¿¬¼ö°­Á : 2018-08-21 0 380 2018-07-28
82 °­¿ø ±¹¸³ÀÇ·á¿ø °ø°øÀÇ·á Consensus conference(3Â÷: °­¿ø±Ç) : 2018-08-20 0 426 2018-07-28
81 ¼­¿ï 2018³âµµ ´ëÇÑÅëÁõÇÐȸ ¾à¹°Ä¡·á ¿¬¼ö°­Á : 2018-08-19 0 484 2018-07-28
80 ¼­¿ï Á¦16ȸ ±è¾È°úº´¿ø ½ÉÆ÷Áö¾ö : 2018-08-19 1 777 2018-07-28
79 ¼­¿ï 2018 ´ëÇÑÀ̺ñÀÎÈÄ°úÀÇ»çȸ °³¿ø¼¼¹Ì³ª : 2018-08-19 0 695 2018-07-28
1401 | 1402 | 1403 | 1404 | 1405 | 1406 | 1407 | 1408 | 1409 | 1410
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷